NewAmsterdam Pharma Company N.V. (NAMS) Stock Ticker
NAMS right now
Market factors today
Unlock the full NAMS picture
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
NAMS stock facts
| Ticker symbol | NAMS |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $2.6B |
| CEO | Michael Harvey Davidson Facp. |
| Employees | 100 |
| Headquarters | Naarden, NH, NL |
| IPO date | 2021-02-09 |
| Website | www.newamsterdampharma.com |
What you can see for NAMS on Tickr
Live NAMS price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the NAMS report.
Rankings
FAQ
What is the ticker symbol for NewAmsterdam Pharma Company N.V.?
The ticker symbol for NewAmsterdam Pharma Company N.V. is NAMS, listed on the NASDAQ.
What is NAMS?
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular…